Ketim Technologies Secures Provisional Approval to Access ORIGINS Birth Cohort Biobank for Postpartum Depression Biomarker Validation

Brisbane, Australia – February 20, 2025 – Ketim Technologies, a leader in biomarker-based diagnostics for perinatal mental health, is proud to announce it has been granted provisional approval as a commercial entity to collaborate with The Kids Research Institute in Western Australia and access the ORIGINS Birth Cohort Biobank.

This milestone follows a rigorous governance process and marks a significant step toward the verification and validation of Ketim Technologies’ pioneering biomarker panel for postpartum depression (PPD). The study will leverage biospecimens and data from ORIGINS participants to confirm findings from the company’s work with the Queensland Family Cohort, enabling the development of a robust AI/ML-driven predictive platform in partnership with Profenso AI.

Through this collaboration, Ketim Technologies will integrate proteomic data generated using Olink® Proteomics by the Australian Genome Research Facility (AGRF) to strengthen the biological signature for PPD and accelerate the creation of an early predictive blood test for use during pregnancy — enabling intervention before symptom onset.

“This approval allows us to expand our research into one of Australia’s most valuable longitudinal cohorts,” said Dr. Clarissa Yates, CEO and Founder of Ketim Technologies. “By combining advanced biomarker discovery with AI-powered analytics, we are moving closer to delivering precision medicine tools that will transform maternal mental health care.”

The ORIGINS collaboration reinforces Ketim Technologies’ mission to revolutionise blood biomarker diagnostics for mental health, starting with postpartum depression, and represents another major milestone in its pathway to clinical validation and commercialisation.

For media inquiries, please contact:
Dr. Clarissa Yates
CEO, Ketim Technologies
clarissa.yates@ketim.com.au